

Clinical Updates in Non–Small Cell Lung Cancer from Madrid

New 1L Standard of Care for *EGFR* Exon 20 Insertion–Mutated Advanced NSCLC

References

Tweet 2 References:

Girard N, Park K, Tang K, et al. Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in *EGFR* exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): primary results from PAPILLON, a randomized phase III global study. Abstract presented at: 2023 ESMO Congress; October 20-24, 2023; Madrid, Spain. Abstract LBA5.

Zhou C, Tang KJ, Cho BC, et al. Amivantamab plus chemotherapy in NSCLC with *EGFR* exon 20 insertions. *N Engl J Med*. Published only October 21, 2023. doi:10.1056/NEJMoa2306441.

Additional References:

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): non-small cell lung cancer (v4.2023). Updated October 18, 2023. Accessed October 27, 2023. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

Girard N, Park K, Tang K, et al. Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in *EGFR* exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): primary results from PAPILLON, a randomized phase III global study. Abstract presented at: 2023 ESMO Congress 2023; October 21, 2023; Madrid, Spain. Abstract LBA5.

Zhou C, Tang KJ, Cho BC, et al. Amivantamab plus chemotherapy in NSCLC with *EGFR* exon 20 insertions. *N Engl J Med*. Published online October 21, 2023. doi:10.1056/NEJMoa2306441

Moore S, Chiu ML, Bushey BS, et al. A novel bispecific antibody targeting *EGFR* and *cMet* is effective against *EGFR* inhibitor-resistant lung tumors. *Cancer Res*. 2016;76(13):3942-3953. doi:10.1158/0008-5472.CAN-15-2833

Nagasaka M, Goto K, Gomez J, et al. Amivantamab in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). *J Thorac Oncol*. 2021;16 (suppl10):S1116. doi:10.1016/j.jtho.2021.08.532

Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an Fc enhanced *EGFR*/*cMet* bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte/macrophage trogocytosis. *Mol Cancer Ther*. 2020;19(10):2044-2056. doi:10.1158/1535-7163.MCT-20-0071

Yun J, Lee SH, Kim SY, et al. Antitumor activity of amivantamab (JNJ-61186372), an *EGFR*-*MET* bispecific antibody, in diverse models of *EGFR* exon 20 insertion-driven NSCLC. *Cancer Discov*. 2020;10(8):1194-1209. doi:10.1158/2159-8290.CD-20-0116

Schaer DA, Geeganage S, Amaladas N, et al. The folate pathway inhibitor pemetrexed pleiotropically enhances effects of cancer immunotherapy. *Clin Cancer Res*. 2019;25(23):7175-7188. doi:10.1158/1078-0432.CCR-19-0433

Schoch S, Gajewski S, Rothfuß J, Hartwig A, Köberle B. Comparative study of the mode of action of clinically approved platinum-based chemotherapeutics. *Int J Mol Sci*. 2020;21(18):6928. doi:0.3390/ijms21186928

Cho BC, Simi A, Sabari J, Vijayaraghavan S, Moores S, Spira A. Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications. *Clin Lung Cancer*. 2023;24(2):89-97. doi:10.1016/j.clcc.2022.11.004

Besse B. Invited Discussant LBA4 and LBA5. Lecture presented at: 2023 ESMO Congress; October 21, 2023; Madrid, Spain.

Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR exon 20 insertion-mutated non-Small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. *J Clin Oncol*. 2021;39(30):3391-3402. doi:10.1200/JCO.21.00662

Basse C, Chabanol H, Bonte PE, Fromantin I, Girard N. Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach. *Lung Cancer*. 2022;173:116-123. doi:10.1016/j.lungcan.2022.09.012.

Glossary

1L, first line
adv, advanced/metastatic
AE, adverse event
BICR, blinded independent central review
carbo/pem, carboplatin + pemetrexed
CME, continuing medical education
CT, chemotherapy
DOR, duration of response
DOT, duration of treatment
EGFR, epidermal growth factor receptor
ESMO, European Society for Medical Oncology
ex20ins, exon 20 insertion mutated
HR, hazard ratio
ICI, immune checkpoint inhibition
NE, not evaluable
NCCN, National Comprehensive Cancer Network
NP, nurse practitioner
NSCLC, non–small cell lung cancer
ORR, overall response rate
OS, overall survival
PA, physician assistant
PFS, progression-free survival
SOC, standard of care
tx, therapy
w/, with